{"gene":"SUMO2","run_date":"2026-04-28T21:42:57","timeline":{"discoveries":[{"year":2001,"finding":"SUMO-2 and SUMO-3 contain the internal consensus SUMO modification site (ψKXE), enabling SAE1/SAE2 (E1) and Ubc9 (E2) to catalyze the formation of polymeric SUMO-2 chains on protein substrates in vitro; SUMO-2 chains were also detected in vivo. This chain-forming capacity is not shared by SUMO-1.","method":"In vitro conjugation assay, in vivo detection of SUMO-2 chains","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis-compatible sequence analysis, replicated in vivo","pmids":["11451954"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of human SUMO-2 (residues 9–93) resolved at 1.2 Å reveals a ubiquitin-like β-barrel flanked by α-helices (βbαββαβ topology) and a surface region near the C-terminus with charge distribution distinct from SUMO-1, potentially explaining their different intracellular localizations.","method":"X-ray crystallography (molecular replacement, R/Rfree 0.119/0.185 at 1.2 Å)","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional inference from charge surface comparison","pmids":["15479240"],"is_preprint":false},{"year":2004,"finding":"SUMO-2 conjugates localize predominantly to the nucleus in HeLa cells; proteomic purification of His6-SUMO-2 conjugates identified novel endogenous substrates including SART1 and hnRNP M, both confirmed as genuine SUMO targets.","method":"Stable cell line expressing His6-SUMO-2, affinity purification from nuclear fractions, mass spectrometry, immunoblot validation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal purification with MS identification and immunoblot confirmation, multiple substrates validated","pmids":["15175327"],"is_preprint":false},{"year":2006,"finding":"SUMO-2 interacts with SIM (SUMO-interacting motif)-containing proteins via a hydrophobic core; the SIM forms a β-strand that binds the β2-strand of SUMO-2 in parallel or antiparallel orientation. Specificity for SUMO-2 versus SUMO-1 is conferred by neighboring acidic residues or phosphorylated serines.","method":"Yeast two-hybrid, bioinformatics, NMR spectroscopy, binding surface mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with functional validation across multiple methods","pmids":["16524884"],"is_preprint":false},{"year":2005,"finding":"PIASy, acting as an E3-like SUMO ligase on mitotic chromosomes, is specifically required for SUMO-2 modification of Topoisomerase-II and other chromosomal substrates in Xenopus egg extracts. PIASy binds mitotic chromosomes and recruits Ubc9 onto chromatin; its depletion abolishes chromosomal SUMO-2 conjugates and blocks anaphase sister chromatid segregation.","method":"Xenopus egg extract depletion, EGFP-SUMO-2 imaging, functional rescue with PIASy mutants, chromosome segregation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — epistasis via depletion, dominant-negative mutants, and defined phenotypic readout (segregation failure)","pmids":["15933717"],"is_preprint":false},{"year":2006,"finding":"SUSP1 (SENP/Ulp family protease) preferentially deconjugates SUMO-2/3 over SUMO-1, acting specifically on substrates bearing three or more SUMO-2/3 moieties; SUSP1 depletion causes redistribution of EGFP-SUMO-2 and EGFP-SUMO-3 into enlarged PML bodies.","method":"Vinyl sulfone inhibitor profiling, model substrate assays, EGFP-SUMO imaging after RNAi depletion","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro activity assays with inhibitors, live-cell imaging, loss-of-function with defined localization phenotype","pmids":["17000875"],"is_preprint":false},{"year":2006,"finding":"Quantitative proteomics using SILAC-labeled HeLa cells stably expressing His6-SUMO-1 or His6-SUMO-2 identified 53 sumoylated proteins; SUMO-1 and SUMO-2 have distinct and overlapping target sets (25 preferential SUMO-1 targets, 19 preferential SUMO-2 targets, 9 shared), indicating non-redundant functions.","method":"Quantitative SILAC proteomics, IMAC enrichment, mass spectrometry, immunoblot confirmation","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 2 — quantitative MS with stable isotope labeling and immunoblot validation across two independent cell lines","pmids":["17000644"],"is_preprint":false},{"year":2008,"finding":"BMAL1 is predominantly conjugated to poly-SUMO2/3 (not SUMO-1) in a circadian manner, peaking at maximum transcriptional activity. SUMO2/3 modification localizes BMAL1 to PML nuclear bodies and promotes both its transactivation and ubiquitin-dependent proteasomal degradation. Mutation of the sumoylation site (K259) inhibits ubiquitination and proteolysis; SUSP1 (SUMO2/3-specific protease) abolishes BMAL1 ubiquitination.","method":"Immunoprecipitation, site-directed mutagenesis, SUMO protease overexpression, proteasome inhibitor treatment, luciferase reporter","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (mutagenesis, protease manipulation, proteasome inhibition) with defined mechanistic outcome","pmids":["18644859"],"is_preprint":false},{"year":2008,"finding":"RanBP2 acts as a SUMO E3 ligase for Borealin (a CPC component), stimulating SUMO2/3 modification in vitro and in vivo. SENP3 directly interacts with Borealin and removes SUMO2/3 from it. This conjugation-deconjugation cycle peaks in early mitosis, defining a mitotic SUMO2/3 regulatory circuit.","method":"In vitro SUMOylation assay with RanBP2, Co-IP, RNAi knockdown, cell synchronization, immunoblot","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro reconstitution plus reciprocal Co-IP and RNAi with cell-cycle-resolved phenotype","pmids":["18946085"],"is_preprint":false},{"year":2010,"finding":"SENP3 deconjugates SUMO2/3 from PML in response to mild oxidative stress (low-dose H2O2); deSUMOylation of PML reduces PML body number and promotes cell proliferation. Only SUMOylated PML (not a SUMOylation-deficient mutant) inhibits cell proliferation, establishing SUMOylation status as a functional determinant.","method":"SENP3 knockdown/overexpression, co-localization, immunoprecipitation, mutant reconstitution, proliferation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined molecular mechanism and mutant rescue","pmids":["20181954"],"is_preprint":false},{"year":2010,"finding":"Proteome-wide mass spectrometry identified 103 SUMO-2 acceptor lysines in endogenous proteins; 76 fit the canonical ψKXE motif, 8 fit an inverted [ED]xK[VILFP] motif, and 16 fit a hydrophobic cluster SUMOylation motif (HCSM). Crosstalk with phosphorylation was observed with a preferred 4-residue spacer between the SUMOylated lysine and the phosphorylated serine.","method":"Site-specific mass spectrometry-based proteomics, SUMO-2 acceptor lysine identification","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — direct MS identification of modification sites at proteome scale, functionally validated for selected substrates","pmids":["20797634"],"is_preprint":false},{"year":2013,"finding":"SUMO-2 modification of huntingtin (HTT) is mediated by the E3 ligase PIAS1 and regulates accumulation of insoluble HTT; PIAS1 is an E3 ligase for both SUMO-1 and SUMO-2 modification of HTT. SUMO-2 modification promotes insoluble HTT accumulation in a manner mimicking proteasome inhibition.","method":"Site-directed mutagenesis defining primary SUMO sites, systematic E3 ligase screen, HeLa cell assays, Drosophila model reduction of dPIAS","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — systematic E3 ligase screen, mutagenesis, and in vivo Drosophila model with defined phenotype","pmids":["23871671"],"is_preprint":false},{"year":2013,"finding":"Cyclin E is dynamically SUMOylated by SUMO2/3 on chromatin in early S phase in Xenopus cell-free system; cyclin E is the predominant SUMO2/3 target on chromatin at this stage and its SUMOylation limits replication origin firing independently of Cdk2 activity.","method":"Xenopus cell-free system, chromatin fractionation, cyclin E depletion/readdition, quantitative immunoblot","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — depletion/reconstitution in cell-free system with defined functional outcome (origin firing control)","pmids":["23673635"],"is_preprint":false},{"year":2014,"finding":"Proteome-wide identification of SUMO2 modification sites using His6-SUMO2(T90K) expressing cells, Lys-C digestion generating diGly remnants, and anti-diGly immunoprecipitation revealed >1000 sumoylated lysines in 539 proteins, including many involved in cell cycle, transcription, and DNA repair.","method":"His6-SUMO2(T90K) expression, Lys-C digestion, diGly immunoprecipitation, mass spectrometry","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 — novel chemical biology/proteomics method with site-level resolution at proteome scale","pmids":["24782567"],"is_preprint":false},{"year":2014,"finding":"SUMO-2 is essential for mouse embryonic development: Sumo2-null embryos exhibit severe developmental delay and die at ~E10.5, whereas Sumo3-null mice are viable, demonstrating that SUMO2 expression level (not functional differences between SUMO2 and SUMO3) is critical for embryogenesis.","method":"Sumo2 and Sumo3 knockout mice, embryonic phenotyping, genetic complementation","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with defined lethal phenotype and genetic epistasis in vivo","pmids":["24891386"],"is_preprint":false},{"year":2014,"finding":"DBC1 modification by SUMO2/3 (not SUMO1) promotes p53-mediated apoptosis under genotoxic stress: ATM/ATR-mediated phosphorylation of DBC1 switches its binding from SENP1 to PIAS3, increasing DBC1 SUMOylation, which enhances DBC1-SIRT1 interaction and releases p53 for transcriptional activation.","method":"Co-IP, site-directed mutagenesis, ATM/ATR inhibitors, SENP1/PIAS3 knockdown, apoptosis assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods defining a complete signaling pathway from kinase to transcription factor","pmids":["25406032"],"is_preprint":false},{"year":2014,"finding":"Quantitative proteomics identified a dynamic set of SUMO-2 conjugates and 755 SUMO-2 sites in response to the DNA damaging agent MMS; SUMOylated chromatin modifiers including JARID1B/KDM5B are ubiquitylated by the SUMO-targeted ubiquitin ligase RNF4 and degraded by the proteasome, while JARID1C is recruited to chromatin to demethylate H3K4.","method":"Quantitative SUMO-2 proteomics (SILAC), MMS treatment, RNF4 knockdown, proteasome inhibition, ChIP","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — quantitative proteomics with functional validation of STUbL pathway and chromatin recruitment","pmids":["25772364"],"is_preprint":false},{"year":2015,"finding":"SUMO-2 (not SUMO-1) selectively modifies the non-native conformation of F508del CFTR NBD1; Hsp27 binds the mutant protein and collaborates with Ubc9 to promote SUMO-2 conjugation at K447, targeting it for degradation via RNF4 and the ubiquitin-proteasome system.","method":"In vitro SUMOylation assay with purified components, mutagenesis of K447, Hsp27 co-IP, fluorescence assay of NBD1 conformation, proteasome inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution plus mutagenesis plus conformational assay with functional degradation readout","pmids":["26627832"],"is_preprint":false},{"year":2016,"finding":"ZNF451-1 functions as a SUMO2/3-specific E3 ligase for PML and selected PML body components; ZNF451-1 RNAi depletion leads to PML stabilization and increased PML body number; the biochemical mechanism of substrate SUMOylation is identical to that used for SUMO chain formation by ZNF451-1.","method":"In vitro SUMOylation assay, mutagenesis, RNAi knockdown, immunofluorescence, PML body quantification","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro reconstitution with mutagenesis and cellular loss-of-function","pmids":["27343429"],"is_preprint":false},{"year":2018,"finding":"SUMO2 conjugation of PCNA (but not SUMO1 or SUMO3), induced on transcribed chromatin by RNAPII-bound helicase RECQ5, recruits histone chaperones CAF1 and FACT via their SUMO-interacting motifs, enhances histone H3.1 deposition at common fragile sites (CFSs), and dislodges RNAPII to resolve transcription-replication conflicts and reduce DSBs.","method":"Proteomic analysis of SUMO2-PCNA interactome, SIM-dependent interaction assays, ChIP, Seahorse/DSB assays, RECQ5-deficient cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — proteomic identification of interaction partners, SIM-dependency shown, functional rescue with defined substrate specificity","pmids":["30006506"],"is_preprint":false},{"year":2018,"finding":"Acetylation of SUMO2 at K11 by an acetyltransferase (reversed by deacetylase SIRT1) impairs SUMO chain formation in vitro and alters chain architecture in cells, favoring K5- and K35-linked chains while inhibiting K7 and K21 linkages; K11 acetyl-mimicking SUMO2 does not affect the STUbL pathway, indicating that non-canonical chains predominate under basal/stress conditions.","method":"In vitro SUMO chain formation assay, SIRT1 deacetylase assay, MS-based SUMO proteomics, acetyl-mimetic mutations","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution plus mutagenesis plus MS-based chain-linkage proteomics","pmids":["30201799"],"is_preprint":false},{"year":2018,"finding":"SUMO2 and SUMO3 (but not SUMO1) redundantly prevent a noncanonical type I interferon response that is independent of IRF3, IRF7, and all known IFN-inducing pathways; loss of sumoylation results in spontaneous IFN production.","method":"Sumo2/Sumo3 double knockout cells, IFN reporter assays, genetic epistasis with IRF3/IRF7 knockouts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double knockouts and pathway mapping via IRF3/IRF7 independence","pmids":["29891701"],"is_preprint":false},{"year":2019,"finding":"SENP6 acts as a poly-SUMO2/3 protease that controls the SUMO modification state of the constitutive centromere-associated network (CCAN) proteins; SENP6 depletion causes SUMO chain accumulation on CCAN subunits (CENP-T, CENP-W, etc.) without proteasomal degradation, impairs centromere assembly, causes G2/M accumulation and micronuclei formation, demonstrating proteolysis-independent SUMO polymer signaling.","method":"SENP6 knockdown, quantitative SUMO proteomics, centromere assembly assays, cell cycle analysis, micronuclei scoring","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — quantitative proteomics with loss-of-function and multiple orthogonal cellular phenotype readouts","pmids":["31485003"],"is_preprint":false},{"year":2009,"finding":"The p150 subunit of chromatin assembly factor 1 (CAF-1) directly and preferentially interacts with SUMO2/3 (via residues 98–105) and is required for delivery of SUMO2/3 to DNA replication foci during S phase; p150 mutants deficient in SUMO2/3 interaction cause major reduction of SUMO2/3 at replication foci.","method":"Direct interaction assays, mutant p150 constructs, BrdU/PCNA co-localization, RNAi knockdown, live-cell imaging","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct interaction mapped, loss-of-function phenotype shown, but single lab with limited mechanistic follow-up","pmids":["19919826"],"is_preprint":false},{"year":2014,"finding":"SENP6 Loop1 insertion is structurally required for SUMO2/3 specificity: a chimeric SENP2 containing SENP6 Loop1 shows increased proteolytic activity toward diSUMO2 and polySUMO2 substrates compared to wild-type SENP2; the crystal structure of SENP2-Loop1 in complex with SUMO2 at 2.15 Å reveals unique contacts at the Loop1-SUMO2 interface.","method":"X-ray crystallography (2.15 Å), chimeric protease construction, in vitro activity assays with diSUMO2 and polySUMO2","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis plus in vitro activity assay","pmids":["24424631"],"is_preprint":false},{"year":2016,"finding":"SUMO2 activates Calcineurin-NFAT signaling via a direct interaction with CnA (calcineurin A), promoting CnA nuclear localization; this effect does not require SUMO2's conjugation activity (ΔGG mutant replicates effects), revealing a sumoylation-independent mechanism of SUMO2 in cardiac hypertrophy.","method":"Cardiac cDNA library screen, NFAT-luciferase reporter, Co-IP (SUMO2-CnA), sumoylation-deficient mutant (ΔGG), AAV9 in vivo cardiac expression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct CnA interaction shown by Co-IP, ΔGG mutant establishes conjugation-independence, in vivo validation","pmids":["27767176"],"is_preprint":false},{"year":2018,"finding":"ATF5 is modified by SUMO2/3 at a conserved consensus site; SUMOylation is elevated in G1 and reduced in G2/M, disrupts ATF5 interaction with centrosomal proteins, and dislodges ATF5 from the centrosome at end of M phase. Blocking ATF5 SUMOylation deregulates the centrosome cycle and causes genomic instability and G2/M arrest.","method":"SUMO site mutagenesis, cell cycle synchronization, Co-IP with centrosomal proteins, centrosome cycle assays, genomic instability scoring","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis plus cell cycle-resolved phenotype, single lab but multiple orthogonal methods","pmids":["29326161"],"is_preprint":false},{"year":2018,"finding":"SENP3 deconjugates SUMO2/3 from MKK7 in macrophages, promoting MKK7 binding to JNK and subsequent JNK phosphorylation upon LPS stimulation; ROS-dependent SENP3 accumulation after LPS drives this deSUMOylation, potentiating TLR4-mediated inflammatory signaling.","method":"Senp3 conditional knockout in myeloid cells, LPS challenge, JNK phosphorylation assays, MKK7 Co-IP, in vivo sepsis model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — conditional knockout mouse with in vivo phenotype, substrate identification, and defined biochemical mechanism","pmids":["29352108"],"is_preprint":false},{"year":2019,"finding":"SENP3 expression is downregulated during osteoclast differentiation; loss of SENP3 in BMDMs increases SUMO3 modification of IRF8 at K310, upregulating NFATc1 expression and promoting osteoclastogenesis; SENP3-conditional knockout mice show enhanced bone loss after ovariectomy.","method":"SENP3 conditional knockout in BMDMs, osteoclast differentiation assays, IRF8 SUMOylation site mutagenesis (K310), Co-IP, in vivo OVX model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — conditional knockout in vivo with substrate site mutagenesis and NFATc1 pathway readout","pmids":["32049023"],"is_preprint":false},{"year":2020,"finding":"Conditional deletion of Sumo2 predominantly in forebrain neurons causes marked impairments in episodic and fear memory and a significant deficit in hippocampal long-term potentiation maintenance, demonstrating that SUMO2 conjugation is critically required for synaptic plasticity and cognitive function.","method":"Conditional Sumo2 knockout mice, behavioral testing (episodic, fear memory), LTP electrophysiology, gene expression analysis","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined electrophysiological and behavioral phenotypes, multiple cognitive tests","pmids":["32910521"],"is_preprint":false},{"year":2021,"finding":"SUMO2 is modified by PIAS4 (E3 ligase) during oxidative stress on TDP-43 at stress granules; SUMO2/3-ylation of TDP-43 by PIAS4 protects it against irreversible aggregation. RNA binding to TDP-43 antagonizes PIAS4-mediated SUMO2/3-ylation, while RNA dissociation promotes it.","method":"PIAS4 depletion, pharmacological inhibition of TDP-43 SUMOylation, stress granule assembly/disassembly assays, RNA binding mutants, Co-IP","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (genetic, pharmacological, RNA binding mutants) defining E3 ligase, stimulus, and functional consequence","pmids":["39982984"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of SENP7 catalytic domain in complex with SUMO2 identifies Loop1 of SENP7 as the structural element responsible for SUMO2/3 isoform specificity, making specific contacts with SUMO2 not seen with other SENP family members.","method":"X-ray crystallography of SENP7-SUMO2 complex, structural comparison, Loop1 mutagenesis","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation of key structural determinants","pmids":["36334780"],"is_preprint":false},{"year":2008,"finding":"SMT3IP1 (nucleolar SUMO-specific protease) preferentially removes SUMO-2 from nucleophosmin (NPM); NPM was identified as an SMT3IP1 binding partner by yeast two-hybrid, and a catalytically inactive SMT3IP1 mutant increased SUMO-2-modified NPM accumulation in a dominant-negative manner.","method":"Yeast two-hybrid, dominant-negative catalytic mutant, Co-IP, immunofluorescence","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — substrate identified by Y2H and dominant-negative approach, single lab","pmids":["18639523"],"is_preprint":false},{"year":2012,"finding":"ARHGAP21 (a RhoGAP protein) is specifically modified by SUMO2/3 at K1443, confirmed by in vitro SUMOylation assay and Co-IP; ARHGAP21 co-localizes with SUMO2/3 in cytoplasm and membrane compartments.","method":"Co-immunoprecipitation, in vitro SUMOylation assay, immunofluorescence, mass spectrometry identification of modified form","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro reconstitution plus in vivo Co-IP and site mapping, single lab","pmids":["22922005"],"is_preprint":false},{"year":2014,"finding":"SUMO-2 promotes formation of the active eIF4F complex by enhancing interaction between eIF4E and eIF4G, stimulating cap-dependent translation of a subset of proteins including cyclin D1 and c-Myc; SUMO-2 overexpression partially rescues the inhibitory effect of the eIF4E/eIF4G interaction disruptor 4EGI-1.","method":"Co-IP of eIF4E-eIF4G, SUMO-2 overexpression and knockdown, 4EGI-1 rescue, translation reporter assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP with functional translation readout, single lab, mechanism not fully resolved","pmids":["24971752"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of SENP1 in noncovalent complex with SUMO2 at 2.62 Å reveals that complex formation is driven by polar interactions; the SUMO2 C-terminal QQTGG motif protrudes into the SENP1 catalytic triad, providing the structural basis for SUMO maturation and deSUMOylation.","method":"X-ray crystallography (2.62 Å, R/Rfree 22.92%/27.66%)","journal":"Acta crystallographica. Section F, Structural biology communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure defining catalytic mechanism and protein-protein interface","pmids":["31045562"],"is_preprint":false},{"year":2011,"finding":"Mouse SUMO-2 inhibits IL-12 secretion in mature dendritic cells by blocking translocation of the p65 subunit of NFκB into the nucleus; SUMO-2 directly modifies IκBα.","method":"Ectopic SUMO-2 expression in DCs, NFκB nuclear translocation assay, IL-12 ELISA, Co-IP of SUMO-2 with IκBα","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP plus functional cytokine and NF-κB readout, single lab","pmids":["21632113"],"is_preprint":false},{"year":2016,"finding":"Depletion of SUMO2 by shRNA enhances and accelerates somatic cell reprogramming to iPSCs (both mouse and human), identifying SUMO2 as a barrier to pluripotency acquisition; the SUMO2 pathway acts independently of c-MYC and in parallel with small-molecule reprogramming enhancers.","method":"Serial shRNA screen, iPSC formation assays, chimera formation, human iPSC generation","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — unbiased screen plus multiple validation approaches (mouse and human), but mechanistic pathway not fully defined","pmids":["26947976"],"is_preprint":false},{"year":2023,"finding":"In mouse brain, Sumo2 is specifically detected at extranuclear compartments including synapses (distinct from nuclear-predominant Sumo1); immunoprecipitation coupled with MS identified shared and specific neuronal targets of Sumo1 versus Sumo2 in vivo.","method":"His6-HA-Sumo2 knockin mice, whole-brain imaging, subcellular fractionation, Co-IP/MS, proximity ligation assays","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 — knockin mouse model with HA-epitope specificity, whole-brain imaging and proteomics, multiple orthogonal validation methods","pmids":["37009224"],"is_preprint":false}],"current_model":"SUMO2 is a ubiquitin-like modifier that, together with SAE1/SAE2 (E1) and Ubc9 (E2), forms polymeric chains on substrates via its internal ψKXE motif; substrate and chain specificity are conferred by SUMO2/3-selective E3 ligases (PIASy, RanBP2, ZNF451-1, PIAS4, MUL1) and reversed by SUMO2/3-selective proteases (SENP3, SENP6, SENP7, SUSP1/SENP8); poly-SUMO2 chains are recognized by STUbL RNF4 to couple sumoylation to ubiquitin-proteasome degradation, while non-degradative SUMO2 polymer signaling regulates centromere assembly, DNA damage response, transcription, replication origin firing, and synaptic plasticity, and SUMO2 can additionally act in a conjugation-independent manner to modulate protein interactions (e.g., CnA nuclear localization)."},"narrative":{"teleology":[{"year":2001,"claim":"Established that SUMO-2, unlike SUMO-1, contains an internal ψKXE motif enabling polymeric chain formation via SAE1/SAE2 and Ubc9, revealing a fundamentally different signaling capacity for this paralog.","evidence":"In vitro reconstitution with purified E1/E2 plus in vivo detection of endogenous SUMO-2 chains","pmids":["11451954"],"confidence":"High","gaps":["Chain linkage specificity (which lysines are used) not determined","Biological function of poly-SUMO2 chains unknown","No E3 ligase involvement assessed"]},{"year":2004,"claim":"High-resolution crystal structure of SUMO-2 revealed the ubiquitin-like βbαββαβ fold and a distinct C-terminal surface charge distribution that distinguishes it from SUMO-1, providing a structural basis for paralog-specific interactions.","evidence":"X-ray crystallography at 1.2 Å resolution","pmids":["15479240"],"confidence":"High","gaps":["No structure of SUMO-2 in complex with binding partners","Functional significance of surface charge differences not tested"]},{"year":2004,"claim":"Proteomic identification of endogenous SUMO-2 conjugates and demonstration of their predominantly nuclear localization established the first substrate landscape for SUMO-2 in human cells.","evidence":"His6-SUMO-2 affinity purification from HeLa nuclear fractions with MS identification and immunoblot validation","pmids":["15175327"],"confidence":"High","gaps":["Modification sites on substrates not mapped","Functional consequences for individual substrates unknown"]},{"year":2005,"claim":"Discovery that PIASy functions as a SUMO-2-specific E3 ligase on mitotic chromosomes, required for Topoisomerase-II SUMOylation and sister chromatid segregation, established the first biological role for targeted SUMO-2 conjugation in cell division.","evidence":"Xenopus egg extract depletion/reconstitution with PIASy mutants and chromosome segregation assays","pmids":["15933717"],"confidence":"High","gaps":["How PIASy achieves SUMO-2 specificity not structurally resolved","Whether other mitotic E3 ligases contribute unknown"]},{"year":2006,"claim":"NMR-based mapping of the SUMO-interacting motif (SIM) binding surface on SUMO-2 showed that SIMs dock as β-strands along β2, with paralog specificity conferred by flanking acidic or phosphorylated residues, providing the molecular basis for SUMO-2-selective protein recognition.","evidence":"NMR spectroscopy, yeast two-hybrid, and bioinformatic analysis","pmids":["16524884"],"confidence":"High","gaps":["SIM-SUMO2 interactions not yet validated for most endogenous targets","Contribution of phosphorylation-dependent SIM switching in vivo unclear"]},{"year":2006,"claim":"Quantitative SILAC proteomics demonstrated that SUMO-1 and SUMO-2 modify substantially non-overlapping substrate sets, and identification of SUSP1/SENP8 as a SUMO-2/3-preferring protease established that both conjugation and deconjugation are paralog-selective.","evidence":"SILAC-labeled HeLa cells with His6-SUMO isoforms; vinyl sulfone inhibitor profiling and RNAi for SUSP1","pmids":["17000644","17000875"],"confidence":"High","gaps":["Determinants of substrate selectivity between SUMO-1 and SUMO-2 not resolved","Full catalog of SUMO-2-specific proteases incomplete"]},{"year":2008,"claim":"Studies on BMAL1 and Borealin revealed that poly-SUMO2/3 modification serves as a signal for ubiquitin-dependent proteasomal degradation and that the conjugation–deconjugation cycle (RanBP2/SENP3) is dynamically regulated during the cell cycle, linking SUMO-2 to both circadian and mitotic regulatory circuits.","evidence":"Mutagenesis of BMAL1 K259, SUMO protease manipulation, proteasome inhibition; in vitro RanBP2-mediated Borealin SUMOylation with SENP3 Co-IP and cell synchronization","pmids":["18644859","18946085"],"confidence":"High","gaps":["Identity of the ubiquitin ligase coupling SUMO2-BMAL1 to ubiquitination not determined at this point","Stoichiometry and kinetics of mitotic SUMO2/3 cycling not measured"]},{"year":2010,"claim":"Proteome-scale mapping of SUMO-2 acceptor lysines revealed canonical ψKXE, inverted, and hydrophobic-cluster motifs, and identified crosstalk with phosphorylation via a conserved spacer, establishing the modification site grammar at systems level.","evidence":"Site-specific mass spectrometry identifying 103 SUMO-2 sites across endogenous proteins","pmids":["20797634"],"confidence":"High","gaps":["Functional consequences of non-canonical motif usage not tested","Kinase-SUMOylation crosstalk validated for only a few substrates"]},{"year":2013,"claim":"SUMO-2 modification of cyclin E on chromatin during early S phase was shown to limit replication origin firing independently of Cdk2, and PIAS1 was identified as an E3 for SUMO-2 conjugation of huntingtin promoting its insoluble accumulation, expanding the functional scope to DNA replication control and neurodegeneration-linked proteostasis.","evidence":"Xenopus cell-free system with cyclin E depletion/reconstitution; systematic E3 screen with HTT mutagenesis and Drosophila model","pmids":["23673635","23871671"],"confidence":"High","gaps":["Mechanism by which SUMO2-cyclin E limits origin firing not defined","Whether SUMO2-HTT aggregation is protective or pathogenic in mammalian neurons unclear"]},{"year":2014,"claim":"Three advances converged: (1) proteome-wide site-level cataloging of >1000 SUMO-2 sites; (2) demonstration that SUMO2 is essential for mouse embryogenesis while SUMO3 is dispensable, attributable to expression level; (3) identification of the ATM/ATR→DBC1→SUMO2/3→SIRT1→p53 apoptotic axis under genotoxic stress.","evidence":"His6-SUMO2(T90K)/diGly proteomics; Sumo2/Sumo3 knockout mice; Co-IP with phospho-switch mutagenesis and apoptosis assays","pmids":["24782567","24891386","25406032"],"confidence":"High","gaps":["Why SUMO2 expression level exceeds SUMO3 in embryonic tissues not explained","Full substrate landscape under DNA damage only partially characterized"]},{"year":2014,"claim":"Structural determination of the SENP6 Loop1 insertion in complex with SUMO2 provided the molecular basis for SUMO2/3-selective chain editing, explaining how poly-SUMO2 chain length is controlled by a dedicated protease architecture.","evidence":"Crystal structure at 2.15 Å of chimeric SENP2-Loop1 with SUMO2 plus in vitro activity assays","pmids":["24424631"],"confidence":"High","gaps":["Full-length SENP6 structure with poly-SUMO2 substrate not available","In vivo validation of Loop1 specificity determinants not yet performed"]},{"year":2014,"claim":"Quantitative SUMO-2 proteomics during DNA damage revealed that RNF4 (STUbL) ubiquitylates SUMOylated chromatin modifiers including KDM5B for proteasomal degradation while recruiting the paralog KDM5C, establishing the SUMO2→RNF4→ubiquitin cascade as a remodeling mechanism for the chromatin damage response.","evidence":"SILAC-based SUMO-2 proteomics after MMS, RNF4 knockdown, ChIP for histone marks","pmids":["25772364"],"confidence":"High","gaps":["Selectivity of RNF4 for specific SUMO2 chain types not resolved","How replacement chromatin modifier recruitment is coordinated unclear"]},{"year":2016,"claim":"ZNF451-1 was identified as a SUMO2/3-specific E3 ligase for PML, and SUMO2 was shown to activate calcineurin-NFAT signaling independently of its conjugation activity via direct binding to CnA, revealing a conjugation-independent mode of SUMO2 action.","evidence":"In vitro SUMOylation and RNAi for ZNF451-1; Co-IP of SUMO2-CnA with ΔGG mutant and AAV9 cardiac delivery","pmids":["27343429","27767176"],"confidence":"High","gaps":["Structural basis of conjugation-independent CnA interaction unknown","Physiological contexts of conjugation-independent SUMO2 functions poorly cataloged"]},{"year":2018,"claim":"Multiple discoveries expanded SUMO2 function to transcription–replication conflict resolution (SUMO2-PCNA recruits CAF1/FACT at fragile sites), chain architecture regulation (K11 acetylation redirects chain linkages), innate immune homeostasis (SUMO2/3 suppress noncanonical type I IFN), and TLR4 inflammatory signaling (SENP3-mediated MKK7 deSUMOylation activates JNK).","evidence":"SUMO2-PCNA interactome with SIM mutants and ChIP; in vitro chain assays with acetyl-mimetic SUMO2; Sumo2/Sumo3 double KO IFN reporter; Senp3 conditional KO macrophages with LPS","pmids":["30006506","30201799","29891701","29352108"],"confidence":"High","gaps":["Acetyltransferase responsible for K11 acetylation not identified","Mechanism of noncanonical IFN induction upon loss of SUMO2/3 undefined","Whether PCNA SUMO2 modification is Ubc9-only or E3-dependent unknown"]},{"year":2019,"claim":"SENP6 was shown to control centromere integrity by editing poly-SUMO2/3 chains on CCAN subunits in a degradation-independent manner, establishing proteolysis-independent SUMO2 polymer signaling as a distinct functional paradigm from the STUbL-dependent pathway.","evidence":"SENP6 knockdown with quantitative SUMO proteomics, centromere assembly assays, cell cycle analysis, and micronuclei scoring","pmids":["31485003"],"confidence":"High","gaps":["How poly-SUMO2 on CCAN disrupts centromere architecture mechanistically not determined","Whether SENP6 acts co-translationally or post-assembly unknown"]},{"year":2020,"claim":"Conditional forebrain deletion of Sumo2 demonstrated that SUMO2 conjugation is essential for hippocampal LTP maintenance and episodic/fear memory, establishing a non-redundant role in adult neuronal physiology.","evidence":"Forebrain-specific Sumo2 conditional knockout mice with electrophysiology and behavioral testing","pmids":["32910521"],"confidence":"High","gaps":["Key synaptic SUMO2 substrates mediating plasticity not identified","Whether SUMO3 compensates partially in these neurons unknown"]},{"year":2022,"claim":"Crystal structure of SENP7 with SUMO2 confirmed that Loop1 is the conserved structural determinant of SUMO2/3 selectivity across the SENP6/7 subfamily, and SUMO2 was shown to localize prominently to synapses (not only nuclei) in mouse brain.","evidence":"X-ray crystallography of SENP7-SUMO2 complex; His6-HA-Sumo2 knockin mice with subcellular fractionation and MS","pmids":["36334780","37009224"],"confidence":"High","gaps":["Synaptic SUMO2 targets and their functional roles remain largely uncharacterized","No full-length SENP7 structure in complex with poly-SUMO2 chain"]},{"year":null,"claim":"Major open questions include: which acetyltransferase modifies SUMO2 at K11 in vivo; how poly-SUMO2 chains on CCAN mechanistically disrupt centromere assembly; the identity of synaptic SUMO2 substrates underlying LTP; the mechanism by which loss of SUMO2/3 triggers noncanonical type I interferon; and the full scope of conjugation-independent SUMO2 functions.","evidence":"","pmids":[],"confidence":"High","gaps":["K11 acetyltransferase identity","Structural basis of poly-SUMO2 chain recognition at centromeres vs. STUbL pathway","Synaptic SUMO2 substrate identification","Mechanism of SUMO2/3-dependent IFN suppression"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0031386","term_label":"protein tag activity","supporting_discovery_ids":[0,10,13]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,7]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[4,12,19,22]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[2,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[38]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,10,13,17]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,8,12,22,26]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[16,19]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[12,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[21,27]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[16,19]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[29,38]}],"complexes":[],"partners":["UBC9","SAE1","SAE2","RNF4","SENP3","SENP6","SENP7","PIASY"],"other_free_text":[]},"mechanistic_narrative":"SUMO2 is a ubiquitin-like post-translational modifier that forms polymeric chains on protein substrates through its internal ψKXE motif, catalyzed by SAE1/SAE2 (E1), Ubc9 (E2), and paralog-selective E3 ligases including PIASy, RanBP2, ZNF451-1, PIAS4, and PIAS1, with chain disassembly mediated by SUMO2/3-specific proteases SENP3, SENP6, and SENP7 whose isoform selectivity is structurally encoded by their Loop1 insertions [PMID:11451954, PMID:15933717, PMID:24424631, PMID:36334780]. Poly-SUMO2 chains serve as signals recognized by the SUMO-targeted ubiquitin ligase RNF4 to couple sumoylation to ubiquitin-dependent proteasomal degradation of substrates such as BMAL1, KDM5B, and misfolded CFTR, while proteolysis-independent SUMO2 polymer signaling regulates centromere assembly (via CCAN subunits), replication origin firing (via cyclin E), transcription–replication conflict resolution (via PCNA-recruited histone chaperones CAF1 and FACT), and innate immune homeostasis by suppressing a noncanonical type I interferon response [PMID:25772364, PMID:26627832, PMID:31485003, PMID:23673635, PMID:30006506, PMID:29891701]. SUMO2 chain architecture is further regulated by acetylation at K11, which redirects linkage specificity, and by crosstalk with phosphorylation on substrates [PMID:30201799, PMID:20797634]. Sumo2 is essential for mouse embryonic development and, in the adult brain, is required at synapses for hippocampal long-term potentiation and memory formation [PMID:24891386, PMID:32910521]."},"prefetch_data":{"uniprot":{"accession":"P61956","full_name":"Small ubiquitin-related modifier 2","aliases":["HSMT3","SMT3 homolog 2","SUMO-3","Sentrin-2","Ubiquitin-like protein SMT3B","Smt3B"],"length_aa":95,"mass_kda":10.9,"function":"Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451 (PubMed:26524494). This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins (PubMed:18408734, PubMed:18538659, PubMed:21965678, PubMed:9556629). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744)","subcellular_location":"Nucleus; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/P61956/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/SUMO2","classification":"Common Essential","n_dependent_lines":259,"n_total_lines":317,"dependency_fraction":0.8170347003154574},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SUMO2","total_profiled":1310},"omim":[{"mim_id":"620480","title":"TRIPARTITE MOTIF FAMILY-LIKE PROTEIN 2; TRIML2","url":"https://www.omim.org/entry/620480"},{"mim_id":"617842","title":"PROTEASOME 26S SUBUNIT, NON-ATPase, 1; PSMD1","url":"https://www.omim.org/entry/617842"},{"mim_id":"617470","title":"UBIQUITIN-SPECIFIC PEPTIDASE-LIKE 1; USPL1","url":"https://www.omim.org/entry/617470"},{"mim_id":"615708","title":"ZINC FINGER PROTEIN 451; ZNF451","url":"https://www.omim.org/entry/615708"},{"mim_id":"614637","title":"DESUMOYLATING ISOPEPTIDASE 1; DESI1","url":"https://www.omim.org/entry/614637"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Calyx","reliability":"Additional"},{"location":"Connecting piece","reliability":"Additional"},{"location":"Flagellar centriole","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SUMO2"},"hgnc":{"alias_symbol":["SMT3B"],"prev_symbol":["SMT3H2"]},"alphafold":{"accession":"P61956","domains":[{"cath_id":"3.10.20.90","chopping":"16-87","consensus_level":"high","plddt":91.9757,"start":16,"end":87}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P61956","model_url":"https://alphafold.ebi.ac.uk/files/AF-P61956-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P61956-F1-predicted_aligned_error_v6.png","plddt_mean":83.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SUMO2","jax_strain_url":"https://www.jax.org/strain/search?query=SUMO2"},"sequence":{"accession":"P61956","fasta_url":"https://rest.uniprot.org/uniprotkb/P61956.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P61956/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P61956"}},"corpus_meta":[{"pmid":"11451954","id":"PMC_11451954","title":"Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11451954","citation_count":694,"is_preprint":false},{"pmid":"16524884","id":"PMC_16524884","title":"Specification of SUMO1- and SUMO2-interacting motifs.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16524884","citation_count":439,"is_preprint":false},{"pmid":"20797634","id":"PMC_20797634","title":"Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20797634","citation_count":269,"is_preprint":false},{"pmid":"17000644","id":"PMC_17000644","title":"Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics.","date":"2006","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/17000644","citation_count":254,"is_preprint":false},{"pmid":"17644626","id":"PMC_17644626","title":"Genetic analysis of SUMOylation in Arabidopsis: conjugation of SUMO1 and SUMO2 to nuclear proteins is essential.","date":"2007","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17644626","citation_count":224,"is_preprint":false},{"pmid":"15175327","id":"PMC_15175327","title":"A proteomic study of SUMO-2 target proteins.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15175327","citation_count":183,"is_preprint":false},{"pmid":"24782567","id":"PMC_24782567","title":"Proteome-wide identification of SUMO2 modification sites.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24782567","citation_count":175,"is_preprint":false},{"pmid":"24891386","id":"PMC_24891386","title":"SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development.","date":"2014","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/24891386","citation_count":161,"is_preprint":false},{"pmid":"18644859","id":"PMC_18644859","title":"Dual modification of BMAL1 by SUMO2/3 and ubiquitin promotes circadian activation of the CLOCK/BMAL1 complex.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18644859","citation_count":137,"is_preprint":false},{"pmid":"17000875","id":"PMC_17000875","title":"SUSP1 antagonizes formation of highly SUMO2/3-conjugated species.","date":"2006","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17000875","citation_count":129,"is_preprint":false},{"pmid":"19033381","id":"PMC_19033381","title":"Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19033381","citation_count":126,"is_preprint":false},{"pmid":"15933717","id":"PMC_15933717","title":"PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15933717","citation_count":123,"is_preprint":false},{"pmid":"34465340","id":"PMC_34465340","title":"Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34465340","citation_count":115,"is_preprint":false},{"pmid":"25772364","id":"PMC_25772364","title":"SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25772364","citation_count":112,"is_preprint":false},{"pmid":"18946085","id":"PMC_18946085","title":"RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18946085","citation_count":96,"is_preprint":false},{"pmid":"23871671","id":"PMC_23871671","title":"SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23871671","citation_count":95,"is_preprint":false},{"pmid":"16567619","id":"PMC_16567619","title":"NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16567619","citation_count":95,"is_preprint":false},{"pmid":"20181954","id":"PMC_20181954","title":"SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20181954","citation_count":91,"is_preprint":false},{"pmid":"12810706","id":"PMC_12810706","title":"Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12810706","citation_count":74,"is_preprint":false},{"pmid":"19240082","id":"PMC_19240082","title":"Novel proteomics strategy brings insight into the prevalence of SUMO-2 target sites.","date":"2009","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/19240082","citation_count":74,"is_preprint":false},{"pmid":"26200910","id":"PMC_26200910","title":"Analysis of the SUMO2 Proteome during HSV-1 Infection.","date":"2015","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26200910","citation_count":64,"is_preprint":false},{"pmid":"15479240","id":"PMC_15479240","title":"Crystal structures of the human SUMO-2 protein at 1.6 A and 1.2 A resolution: implication on the functional differences of SUMO proteins.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15479240","citation_count":64,"is_preprint":false},{"pmid":"24651501","id":"PMC_24651501","title":"Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies.","date":"2014","source":"Nature protocols","url":"https://pubmed.ncbi.nlm.nih.gov/24651501","citation_count":64,"is_preprint":false},{"pmid":"31485003","id":"PMC_31485003","title":"The poly-SUMO2/3 protease SENP6 enables assembly of the constitutive centromere-associated network by group deSUMOylation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31485003","citation_count":61,"is_preprint":false},{"pmid":"21898723","id":"PMC_21898723","title":"Expanded click conjugation of recombinant proteins with ubiquitin-like modifiers reveals altered substrate preference of SUMO2-modified Ubc9.","date":"2011","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/21898723","citation_count":57,"is_preprint":false},{"pmid":"25244549","id":"PMC_25244549","title":"Traceless preparation of C-terminal α-ketoacids for chemical protein synthesis by α-ketoacid-hydroxylamine ligation: synthesis of SUMO2/3.","date":"2014","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/25244549","citation_count":53,"is_preprint":false},{"pmid":"30006506","id":"PMC_30006506","title":"SUMO2 conjugation of PCNA facilitates chromatin remodeling to resolve transcription-replication conflicts.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30006506","citation_count":50,"is_preprint":false},{"pmid":"26947976","id":"PMC_26947976","title":"A Serial shRNA Screen for Roadblocks to Reprogramming Identifies the Protein Modifier SUMO2.","date":"2016","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26947976","citation_count":49,"is_preprint":false},{"pmid":"29891701","id":"PMC_29891701","title":"SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29891701","citation_count":47,"is_preprint":false},{"pmid":"9833880","id":"PMC_9833880","title":"Insertion of a bovine SMT3B gene in NS4B and duplication of NS3 in a bovine viral diarrhea virus genome correlate with the cytopathogenicity of the virus.","date":"1998","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/9833880","citation_count":43,"is_preprint":false},{"pmid":"29352108","id":"PMC_29352108","title":"DeSUMOylation of MKK7 kinase by the SUMO2/3 protease SENP3 potentiates lipopolysaccharide-induced inflammatory signaling in macrophages.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29352108","citation_count":43,"is_preprint":false},{"pmid":"21830832","id":"PMC_21830832","title":"Absolute SILAC-compatible expression strain allows Sumo-2 copy number determination in clinical samples.","date":"2011","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/21830832","citation_count":41,"is_preprint":false},{"pmid":"25406032","id":"PMC_25406032","title":"Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25406032","citation_count":39,"is_preprint":false},{"pmid":"9891849","id":"PMC_9891849","title":"Characterization of mouse ubiquitin-like SMT3A and SMT3B cDNAs and gene/pseudogenes.","date":"1998","source":"Biochemistry and molecular biology international","url":"https://pubmed.ncbi.nlm.nih.gov/9891849","citation_count":37,"is_preprint":false},{"pmid":"11283016","id":"PMC_11283016","title":"A novel human striated muscle RING zinc finger protein, SMRZ, interacts with SMT3b via its RING domain.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11283016","citation_count":36,"is_preprint":false},{"pmid":"25352045","id":"PMC_25352045","title":"SUMO2/3 is associated with ubiquitinated protein aggregates in the mouse neocortex after middle cerebral artery occlusion.","date":"2014","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25352045","citation_count":36,"is_preprint":false},{"pmid":"22891650","id":"PMC_22891650","title":"Moderate hypothermia induces marked increase in levels and nuclear accumulation of SUMO2/3-conjugated proteins in neurons.","date":"2012","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22891650","citation_count":36,"is_preprint":false},{"pmid":"32049023","id":"PMC_32049023","title":"SENP3 Suppresses Osteoclastogenesis by De-conjugating SUMO2/3 from IRF8 in Bone Marrow-Derived Monocytes.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32049023","citation_count":35,"is_preprint":false},{"pmid":"25497329","id":"PMC_25497329","title":"Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells.","date":"2014","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/25497329","citation_count":32,"is_preprint":false},{"pmid":"25857621","id":"PMC_25857621","title":"Involvement of activated SUMO-2 conjugation in cardiomyopathy.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25857621","citation_count":31,"is_preprint":false},{"pmid":"26511642","id":"PMC_26511642","title":"SENP3 regulates the global protein turnover and the Sp1 level via antagonizing SUMO2/3-targeted ubiquitination and degradation.","date":"2015","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/26511642","citation_count":29,"is_preprint":false},{"pmid":"27343429","id":"PMC_27343429","title":"The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27343429","citation_count":29,"is_preprint":false},{"pmid":"38201212","id":"PMC_38201212","title":"Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38201212","citation_count":28,"is_preprint":false},{"pmid":"30201799","id":"PMC_30201799","title":"Acetylation of SUMO2 at lysine 11 favors the formation of non-canonical SUMO chains.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30201799","citation_count":28,"is_preprint":false},{"pmid":"21291420","id":"PMC_21291420","title":"SUMO2 and SUMO3 transcription is differentially regulated by oxidative stress in an Sp1-dependent manner.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21291420","citation_count":28,"is_preprint":false},{"pmid":"26627832","id":"PMC_26627832","title":"Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26627832","citation_count":26,"is_preprint":false},{"pmid":"34032148","id":"PMC_34032148","title":"LncRNA SNHG3 Promotes Proliferation and Metastasis of Non-Small-Cell Lung Cancer Cells Through miR-515-5p/SUMO2 Axis.","date":"2021","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34032148","citation_count":25,"is_preprint":false},{"pmid":"24971350","id":"PMC_24971350","title":"High glucose induces sumoylation of Smad4 via SUMO2/3 in mesangial cells.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24971350","citation_count":25,"is_preprint":false},{"pmid":"23358114","id":"PMC_23358114","title":"PIASγ enhanced SUMO-2 modification of Nurr1 activation-function-1 domain limits Nurr1 transcriptional synergy.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23358114","citation_count":24,"is_preprint":false},{"pmid":"24971888","id":"PMC_24971888","title":"Comprehensive identification of SUMO2/3 targets and their dynamics during mitosis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24971888","citation_count":22,"is_preprint":false},{"pmid":"21632113","id":"PMC_21632113","title":"The mouse small ubiquitin-like modifier-2 (SUMO-2) inhibits interleukin-12 (IL-12) production in mature dendritic cells by blocking the translocation of the p65 subunit of NFκB into the nucleus.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21632113","citation_count":22,"is_preprint":false},{"pmid":"30559154","id":"PMC_30559154","title":"SUMOylation by SUMO2 is implicated in the degradation of misfolded ataxin-7 via RNF4 in SCA7 models.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30559154","citation_count":21,"is_preprint":false},{"pmid":"25607652","id":"PMC_25607652","title":"KSHV latent protein LANA2 inhibits sumo2 modification of p53.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25607652","citation_count":20,"is_preprint":false},{"pmid":"19919826","id":"PMC_19919826","title":"The p150 subunit of CAF-1 causes association of SUMO2/3 with the DNA replication foci.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19919826","citation_count":19,"is_preprint":false},{"pmid":"23673635","id":"PMC_23673635","title":"SUMO2/3 modification of cyclin E contributes to the control of replication origin firing.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23673635","citation_count":19,"is_preprint":false},{"pmid":"39982984","id":"PMC_39982984","title":"SUMO2/3 conjugation of TDP-43 protects against aggregation.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39982984","citation_count":18,"is_preprint":false},{"pmid":"22178731","id":"PMC_22178731","title":"Ubiquitin-intein and SUMO2-intein fusion systems for enhanced protein production and purification.","date":"2011","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/22178731","citation_count":18,"is_preprint":false},{"pmid":"35864967","id":"PMC_35864967","title":"SUMOylation of Nuclear γ-Actin by SUMO2 supports DNA Damage Repair against Myocardial Ischemia-Reperfusion Injury.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35864967","citation_count":17,"is_preprint":false},{"pmid":"32910521","id":"PMC_32910521","title":"Small ubiquitin-like modifier 2 (SUMO2) is critical for memory processes in mice.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32910521","citation_count":17,"is_preprint":false},{"pmid":"29700214","id":"PMC_29700214","title":"Silencing SUMO2 promotes protection against degradation and apoptosis of nucleus pulposus cells through p53 signaling pathway in intervertebral disc degeneration.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/29700214","citation_count":17,"is_preprint":false},{"pmid":"27016777","id":"PMC_27016777","title":"Dynamic regulation of HIF1Α stability by SUMO2/3 and SENP3 in the human placenta.","date":"2016","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/27016777","citation_count":16,"is_preprint":false},{"pmid":"27071615","id":"PMC_27071615","title":"IL-6 induced proliferation and cytotoxic activity of CD8(+) T cells is elevated by SUMO2 overexpression.","date":"2016","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/27071615","citation_count":16,"is_preprint":false},{"pmid":"24424631","id":"PMC_24424631","title":"Structural insights into the SENP6 Loop1 structure in complex with SUMO2.","date":"2014","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/24424631","citation_count":16,"is_preprint":false},{"pmid":"22945749","id":"PMC_22945749","title":"Transient ischemia induces massive nuclear accumulation of SUMO2/3-conjugated proteins in spinal cord neurons.","date":"2012","source":"Spinal cord","url":"https://pubmed.ncbi.nlm.nih.gov/22945749","citation_count":16,"is_preprint":false},{"pmid":"38327870","id":"PMC_38327870","title":"SumoPred-PLM: human SUMOylation and SUMO2/3 sites Prediction using Pre-trained Protein Language Model.","date":"2024","source":"NAR genomics and bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/38327870","citation_count":15,"is_preprint":false},{"pmid":"18639523","id":"PMC_18639523","title":"SMT3IP1, a nucleolar SUMO-specific protease, deconjugates SUMO-2 from nucleolar and cytoplasmic nucleophosmin.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18639523","citation_count":15,"is_preprint":false},{"pmid":"27767176","id":"PMC_27767176","title":"Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27767176","citation_count":14,"is_preprint":false},{"pmid":"35487252","id":"PMC_35487252","title":"SUMO2-mediated SUMOylation of SH3GLB1 promotes ionizing radiation-induced hypertrophic cardiomyopathy through mitophagy activation.","date":"2022","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35487252","citation_count":14,"is_preprint":false},{"pmid":"31584834","id":"PMC_31584834","title":"SUMO2 regulates vascular endothelial function and oxidative stress in mice.","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31584834","citation_count":13,"is_preprint":false},{"pmid":"35235714","id":"PMC_35235714","title":"Multiplexed Delivery of Synthetic (Un)Conjugatable Ubiquitin and SUMO2 Enables Simultaneous Monitoring of Their Localization and Function in Live Cells.","date":"2022","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35235714","citation_count":13,"is_preprint":false},{"pmid":"32892251","id":"PMC_32892251","title":"Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors.","date":"2020","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32892251","citation_count":13,"is_preprint":false},{"pmid":"25762490","id":"PMC_25762490","title":"SUMO2 overexpression enhances the generation and function of interleukin-17-producing CD8⁺ T cells in mice.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25762490","citation_count":12,"is_preprint":false},{"pmid":"18081309","id":"PMC_18081309","title":"Basic folded and low-populated locally disordered conformers of SUMO-2 characterized by NMR spectroscopy at varying pressures.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18081309","citation_count":12,"is_preprint":false},{"pmid":"29326161","id":"PMC_29326161","title":"SUMO2/3 modification of activating transcription factor 5 (ATF5) controls its dynamic translocation at the centrosome.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29326161","citation_count":12,"is_preprint":false},{"pmid":"36334780","id":"PMC_36334780","title":"Structural Basis for the SUMO2 Isoform Specificity of SENP7.","date":"2022","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/36334780","citation_count":11,"is_preprint":false},{"pmid":"31830143","id":"PMC_31830143","title":"Identification of viral SIM-SUMO2-interaction inhibitors for treating primary effusion lymphoma.","date":"2019","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/31830143","citation_count":11,"is_preprint":false},{"pmid":"25748227","id":"PMC_25748227","title":"Regulation of SUMO2 target proteins by the proteasome in human cells exposed to replication stress.","date":"2015","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/25748227","citation_count":11,"is_preprint":false},{"pmid":"37942585","id":"PMC_37942585","title":"NDP52 SUMOylation contributes to low-dose X-rays-induced cardiac hypertrophy through PINK1/Parkin-mediated mitophagy via MUL1/SUMO2 signalling.","date":"2023","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37942585","citation_count":11,"is_preprint":false},{"pmid":"34257372","id":"PMC_34257372","title":"Differential effects of SUMO1 and SUMO2 on circadian protein PER2 stability and function.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34257372","citation_count":11,"is_preprint":false},{"pmid":"37009224","id":"PMC_37009224","title":"Characterizing the differential distribution and targets of Sumo1 and Sumo2 in the mouse brain.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37009224","citation_count":10,"is_preprint":false},{"pmid":"31625212","id":"PMC_31625212","title":"The requirement of SUMO2/3 for SENP2 mediated extraembryonic and embryonic development.","date":"2019","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/31625212","citation_count":10,"is_preprint":false},{"pmid":"22922005","id":"PMC_22922005","title":"Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22922005","citation_count":10,"is_preprint":false},{"pmid":"33989451","id":"PMC_33989451","title":"Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33989451","citation_count":9,"is_preprint":false},{"pmid":"33539797","id":"PMC_33539797","title":"Selective-cerebral-hypothermia-induced neuroprotection against-focal cerebral ischemia/reperfusion injury is associated with an increase in SUMO2/3 conjugation.","date":"2021","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/33539797","citation_count":9,"is_preprint":false},{"pmid":"36346822","id":"PMC_36346822","title":"A structural dynamics model for how CPEB3 binding to SUMO2 can regulate translational control in dendritic spines.","date":"2022","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/36346822","citation_count":9,"is_preprint":false},{"pmid":"25245533","id":"PMC_25245533","title":"Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25245533","citation_count":9,"is_preprint":false},{"pmid":"33732350","id":"PMC_33732350","title":"Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33732350","citation_count":8,"is_preprint":false},{"pmid":"34174262","id":"PMC_34174262","title":"Prasugrel anti-ischemic effect in rats: Modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories.","date":"2021","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34174262","citation_count":8,"is_preprint":false},{"pmid":"37473957","id":"PMC_37473957","title":"Overexpression of SENP3 promotes PPAR-γ transcription through the increase of HIF-1α stability via SUMO2/3 and participates in molecular mechanisms of osteoporosis.","date":"2023","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37473957","citation_count":8,"is_preprint":false},{"pmid":"37338025","id":"PMC_37338025","title":"SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.","date":"2023","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37338025","citation_count":7,"is_preprint":false},{"pmid":"38513457","id":"PMC_38513457","title":"FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness.","date":"2024","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38513457","citation_count":7,"is_preprint":false},{"pmid":"29512695","id":"PMC_29512695","title":"SUMO2 modification of Aurora B and its impact on follicular development and atresia in the mouse ovary.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29512695","citation_count":7,"is_preprint":false},{"pmid":"31045562","id":"PMC_31045562","title":"Noncovalent structure of SENP1 in complex with SUMO2.","date":"2019","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/31045562","citation_count":7,"is_preprint":false},{"pmid":"36656084","id":"PMC_36656084","title":"The allosteric effect of the upper half of SENP1 contributes to its substrate selectivity for SUMO1 over SUMO2.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/36656084","citation_count":7,"is_preprint":false},{"pmid":"39000276","id":"PMC_39000276","title":"SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39000276","citation_count":6,"is_preprint":false},{"pmid":"18243776","id":"PMC_18243776","title":"Schistosoma mansoni encodes SMT3B and SMT3C molecules responsible for post-translational modification of cellular proteins.","date":"2007","source":"Parasitology international","url":"https://pubmed.ncbi.nlm.nih.gov/18243776","citation_count":6,"is_preprint":false},{"pmid":"37403456","id":"PMC_37403456","title":"SENP5 deteriorates traumatic brain injury via SUMO2-dependent suppression of E2F1 SUMOylation.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37403456","citation_count":6,"is_preprint":false},{"pmid":"40047257","id":"PMC_40047257","title":"Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40047257","citation_count":6,"is_preprint":false},{"pmid":"24971752","id":"PMC_24971752","title":"SUMO-2 promotes mRNA translation by enhancing interaction between eIF4E and eIF4G.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24971752","citation_count":6,"is_preprint":false},{"pmid":"37890757","id":"PMC_37890757","title":"Aberrant SUMO2/3 modification of RUNX1 upon SENP1 inhibition is linked to the development of diabetic retinopathy in mice.","date":"2023","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/37890757","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49744,"output_tokens":9351,"usd":0.144749},"stage2":{"model":"claude-opus-4-6","input_tokens":13283,"output_tokens":4770,"usd":0.278498},"total_usd":0.423247,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"SUMO-2 and SUMO-3 contain the internal consensus SUMO modification site (ψKXE), enabling SAE1/SAE2 (E1) and Ubc9 (E2) to catalyze the formation of polymeric SUMO-2 chains on protein substrates in vitro; SUMO-2 chains were also detected in vivo. This chain-forming capacity is not shared by SUMO-1.\",\n      \"method\": \"In vitro conjugation assay, in vivo detection of SUMO-2 chains\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis-compatible sequence analysis, replicated in vivo\",\n      \"pmids\": [\"11451954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of human SUMO-2 (residues 9–93) resolved at 1.2 Å reveals a ubiquitin-like β-barrel flanked by α-helices (βbαββαβ topology) and a surface region near the C-terminus with charge distribution distinct from SUMO-1, potentially explaining their different intracellular localizations.\",\n      \"method\": \"X-ray crystallography (molecular replacement, R/Rfree 0.119/0.185 at 1.2 Å)\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional inference from charge surface comparison\",\n      \"pmids\": [\"15479240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SUMO-2 conjugates localize predominantly to the nucleus in HeLa cells; proteomic purification of His6-SUMO-2 conjugates identified novel endogenous substrates including SART1 and hnRNP M, both confirmed as genuine SUMO targets.\",\n      \"method\": \"Stable cell line expressing His6-SUMO-2, affinity purification from nuclear fractions, mass spectrometry, immunoblot validation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal purification with MS identification and immunoblot confirmation, multiple substrates validated\",\n      \"pmids\": [\"15175327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SUMO-2 interacts with SIM (SUMO-interacting motif)-containing proteins via a hydrophobic core; the SIM forms a β-strand that binds the β2-strand of SUMO-2 in parallel or antiparallel orientation. Specificity for SUMO-2 versus SUMO-1 is conferred by neighboring acidic residues or phosphorylated serines.\",\n      \"method\": \"Yeast two-hybrid, bioinformatics, NMR spectroscopy, binding surface mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with functional validation across multiple methods\",\n      \"pmids\": [\"16524884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PIASy, acting as an E3-like SUMO ligase on mitotic chromosomes, is specifically required for SUMO-2 modification of Topoisomerase-II and other chromosomal substrates in Xenopus egg extracts. PIASy binds mitotic chromosomes and recruits Ubc9 onto chromatin; its depletion abolishes chromosomal SUMO-2 conjugates and blocks anaphase sister chromatid segregation.\",\n      \"method\": \"Xenopus egg extract depletion, EGFP-SUMO-2 imaging, functional rescue with PIASy mutants, chromosome segregation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via depletion, dominant-negative mutants, and defined phenotypic readout (segregation failure)\",\n      \"pmids\": [\"15933717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SUSP1 (SENP/Ulp family protease) preferentially deconjugates SUMO-2/3 over SUMO-1, acting specifically on substrates bearing three or more SUMO-2/3 moieties; SUSP1 depletion causes redistribution of EGFP-SUMO-2 and EGFP-SUMO-3 into enlarged PML bodies.\",\n      \"method\": \"Vinyl sulfone inhibitor profiling, model substrate assays, EGFP-SUMO imaging after RNAi depletion\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro activity assays with inhibitors, live-cell imaging, loss-of-function with defined localization phenotype\",\n      \"pmids\": [\"17000875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Quantitative proteomics using SILAC-labeled HeLa cells stably expressing His6-SUMO-1 or His6-SUMO-2 identified 53 sumoylated proteins; SUMO-1 and SUMO-2 have distinct and overlapping target sets (25 preferential SUMO-1 targets, 19 preferential SUMO-2 targets, 9 shared), indicating non-redundant functions.\",\n      \"method\": \"Quantitative SILAC proteomics, IMAC enrichment, mass spectrometry, immunoblot confirmation\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative MS with stable isotope labeling and immunoblot validation across two independent cell lines\",\n      \"pmids\": [\"17000644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMAL1 is predominantly conjugated to poly-SUMO2/3 (not SUMO-1) in a circadian manner, peaking at maximum transcriptional activity. SUMO2/3 modification localizes BMAL1 to PML nuclear bodies and promotes both its transactivation and ubiquitin-dependent proteasomal degradation. Mutation of the sumoylation site (K259) inhibits ubiquitination and proteolysis; SUSP1 (SUMO2/3-specific protease) abolishes BMAL1 ubiquitination.\",\n      \"method\": \"Immunoprecipitation, site-directed mutagenesis, SUMO protease overexpression, proteasome inhibitor treatment, luciferase reporter\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (mutagenesis, protease manipulation, proteasome inhibition) with defined mechanistic outcome\",\n      \"pmids\": [\"18644859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RanBP2 acts as a SUMO E3 ligase for Borealin (a CPC component), stimulating SUMO2/3 modification in vitro and in vivo. SENP3 directly interacts with Borealin and removes SUMO2/3 from it. This conjugation-deconjugation cycle peaks in early mitosis, defining a mitotic SUMO2/3 regulatory circuit.\",\n      \"method\": \"In vitro SUMOylation assay with RanBP2, Co-IP, RNAi knockdown, cell synchronization, immunoblot\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro reconstitution plus reciprocal Co-IP and RNAi with cell-cycle-resolved phenotype\",\n      \"pmids\": [\"18946085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SENP3 deconjugates SUMO2/3 from PML in response to mild oxidative stress (low-dose H2O2); deSUMOylation of PML reduces PML body number and promotes cell proliferation. Only SUMOylated PML (not a SUMOylation-deficient mutant) inhibits cell proliferation, establishing SUMOylation status as a functional determinant.\",\n      \"method\": \"SENP3 knockdown/overexpression, co-localization, immunoprecipitation, mutant reconstitution, proliferation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular mechanism and mutant rescue\",\n      \"pmids\": [\"20181954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Proteome-wide mass spectrometry identified 103 SUMO-2 acceptor lysines in endogenous proteins; 76 fit the canonical ψKXE motif, 8 fit an inverted [ED]xK[VILFP] motif, and 16 fit a hydrophobic cluster SUMOylation motif (HCSM). Crosstalk with phosphorylation was observed with a preferred 4-residue spacer between the SUMOylated lysine and the phosphorylated serine.\",\n      \"method\": \"Site-specific mass spectrometry-based proteomics, SUMO-2 acceptor lysine identification\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct MS identification of modification sites at proteome scale, functionally validated for selected substrates\",\n      \"pmids\": [\"20797634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SUMO-2 modification of huntingtin (HTT) is mediated by the E3 ligase PIAS1 and regulates accumulation of insoluble HTT; PIAS1 is an E3 ligase for both SUMO-1 and SUMO-2 modification of HTT. SUMO-2 modification promotes insoluble HTT accumulation in a manner mimicking proteasome inhibition.\",\n      \"method\": \"Site-directed mutagenesis defining primary SUMO sites, systematic E3 ligase screen, HeLa cell assays, Drosophila model reduction of dPIAS\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic E3 ligase screen, mutagenesis, and in vivo Drosophila model with defined phenotype\",\n      \"pmids\": [\"23871671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cyclin E is dynamically SUMOylated by SUMO2/3 on chromatin in early S phase in Xenopus cell-free system; cyclin E is the predominant SUMO2/3 target on chromatin at this stage and its SUMOylation limits replication origin firing independently of Cdk2 activity.\",\n      \"method\": \"Xenopus cell-free system, chromatin fractionation, cyclin E depletion/readdition, quantitative immunoblot\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — depletion/reconstitution in cell-free system with defined functional outcome (origin firing control)\",\n      \"pmids\": [\"23673635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Proteome-wide identification of SUMO2 modification sites using His6-SUMO2(T90K) expressing cells, Lys-C digestion generating diGly remnants, and anti-diGly immunoprecipitation revealed >1000 sumoylated lysines in 539 proteins, including many involved in cell cycle, transcription, and DNA repair.\",\n      \"method\": \"His6-SUMO2(T90K) expression, Lys-C digestion, diGly immunoprecipitation, mass spectrometry\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — novel chemical biology/proteomics method with site-level resolution at proteome scale\",\n      \"pmids\": [\"24782567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SUMO-2 is essential for mouse embryonic development: Sumo2-null embryos exhibit severe developmental delay and die at ~E10.5, whereas Sumo3-null mice are viable, demonstrating that SUMO2 expression level (not functional differences between SUMO2 and SUMO3) is critical for embryogenesis.\",\n      \"method\": \"Sumo2 and Sumo3 knockout mice, embryonic phenotyping, genetic complementation\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with defined lethal phenotype and genetic epistasis in vivo\",\n      \"pmids\": [\"24891386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DBC1 modification by SUMO2/3 (not SUMO1) promotes p53-mediated apoptosis under genotoxic stress: ATM/ATR-mediated phosphorylation of DBC1 switches its binding from SENP1 to PIAS3, increasing DBC1 SUMOylation, which enhances DBC1-SIRT1 interaction and releases p53 for transcriptional activation.\",\n      \"method\": \"Co-IP, site-directed mutagenesis, ATM/ATR inhibitors, SENP1/PIAS3 knockdown, apoptosis assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods defining a complete signaling pathway from kinase to transcription factor\",\n      \"pmids\": [\"25406032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Quantitative proteomics identified a dynamic set of SUMO-2 conjugates and 755 SUMO-2 sites in response to the DNA damaging agent MMS; SUMOylated chromatin modifiers including JARID1B/KDM5B are ubiquitylated by the SUMO-targeted ubiquitin ligase RNF4 and degraded by the proteasome, while JARID1C is recruited to chromatin to demethylate H3K4.\",\n      \"method\": \"Quantitative SUMO-2 proteomics (SILAC), MMS treatment, RNF4 knockdown, proteasome inhibition, ChIP\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics with functional validation of STUbL pathway and chromatin recruitment\",\n      \"pmids\": [\"25772364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SUMO-2 (not SUMO-1) selectively modifies the non-native conformation of F508del CFTR NBD1; Hsp27 binds the mutant protein and collaborates with Ubc9 to promote SUMO-2 conjugation at K447, targeting it for degradation via RNF4 and the ubiquitin-proteasome system.\",\n      \"method\": \"In vitro SUMOylation assay with purified components, mutagenesis of K447, Hsp27 co-IP, fluorescence assay of NBD1 conformation, proteasome inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus mutagenesis plus conformational assay with functional degradation readout\",\n      \"pmids\": [\"26627832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF451-1 functions as a SUMO2/3-specific E3 ligase for PML and selected PML body components; ZNF451-1 RNAi depletion leads to PML stabilization and increased PML body number; the biochemical mechanism of substrate SUMOylation is identical to that used for SUMO chain formation by ZNF451-1.\",\n      \"method\": \"In vitro SUMOylation assay, mutagenesis, RNAi knockdown, immunofluorescence, PML body quantification\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro reconstitution with mutagenesis and cellular loss-of-function\",\n      \"pmids\": [\"27343429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SUMO2 conjugation of PCNA (but not SUMO1 or SUMO3), induced on transcribed chromatin by RNAPII-bound helicase RECQ5, recruits histone chaperones CAF1 and FACT via their SUMO-interacting motifs, enhances histone H3.1 deposition at common fragile sites (CFSs), and dislodges RNAPII to resolve transcription-replication conflicts and reduce DSBs.\",\n      \"method\": \"Proteomic analysis of SUMO2-PCNA interactome, SIM-dependent interaction assays, ChIP, Seahorse/DSB assays, RECQ5-deficient cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — proteomic identification of interaction partners, SIM-dependency shown, functional rescue with defined substrate specificity\",\n      \"pmids\": [\"30006506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Acetylation of SUMO2 at K11 by an acetyltransferase (reversed by deacetylase SIRT1) impairs SUMO chain formation in vitro and alters chain architecture in cells, favoring K5- and K35-linked chains while inhibiting K7 and K21 linkages; K11 acetyl-mimicking SUMO2 does not affect the STUbL pathway, indicating that non-canonical chains predominate under basal/stress conditions.\",\n      \"method\": \"In vitro SUMO chain formation assay, SIRT1 deacetylase assay, MS-based SUMO proteomics, acetyl-mimetic mutations\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus mutagenesis plus MS-based chain-linkage proteomics\",\n      \"pmids\": [\"30201799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SUMO2 and SUMO3 (but not SUMO1) redundantly prevent a noncanonical type I interferon response that is independent of IRF3, IRF7, and all known IFN-inducing pathways; loss of sumoylation results in spontaneous IFN production.\",\n      \"method\": \"Sumo2/Sumo3 double knockout cells, IFN reporter assays, genetic epistasis with IRF3/IRF7 knockouts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double knockouts and pathway mapping via IRF3/IRF7 independence\",\n      \"pmids\": [\"29891701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SENP6 acts as a poly-SUMO2/3 protease that controls the SUMO modification state of the constitutive centromere-associated network (CCAN) proteins; SENP6 depletion causes SUMO chain accumulation on CCAN subunits (CENP-T, CENP-W, etc.) without proteasomal degradation, impairs centromere assembly, causes G2/M accumulation and micronuclei formation, demonstrating proteolysis-independent SUMO polymer signaling.\",\n      \"method\": \"SENP6 knockdown, quantitative SUMO proteomics, centromere assembly assays, cell cycle analysis, micronuclei scoring\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics with loss-of-function and multiple orthogonal cellular phenotype readouts\",\n      \"pmids\": [\"31485003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The p150 subunit of chromatin assembly factor 1 (CAF-1) directly and preferentially interacts with SUMO2/3 (via residues 98–105) and is required for delivery of SUMO2/3 to DNA replication foci during S phase; p150 mutants deficient in SUMO2/3 interaction cause major reduction of SUMO2/3 at replication foci.\",\n      \"method\": \"Direct interaction assays, mutant p150 constructs, BrdU/PCNA co-localization, RNAi knockdown, live-cell imaging\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction mapped, loss-of-function phenotype shown, but single lab with limited mechanistic follow-up\",\n      \"pmids\": [\"19919826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SENP6 Loop1 insertion is structurally required for SUMO2/3 specificity: a chimeric SENP2 containing SENP6 Loop1 shows increased proteolytic activity toward diSUMO2 and polySUMO2 substrates compared to wild-type SENP2; the crystal structure of SENP2-Loop1 in complex with SUMO2 at 2.15 Å reveals unique contacts at the Loop1-SUMO2 interface.\",\n      \"method\": \"X-ray crystallography (2.15 Å), chimeric protease construction, in vitro activity assays with diSUMO2 and polySUMO2\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis plus in vitro activity assay\",\n      \"pmids\": [\"24424631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SUMO2 activates Calcineurin-NFAT signaling via a direct interaction with CnA (calcineurin A), promoting CnA nuclear localization; this effect does not require SUMO2's conjugation activity (ΔGG mutant replicates effects), revealing a sumoylation-independent mechanism of SUMO2 in cardiac hypertrophy.\",\n      \"method\": \"Cardiac cDNA library screen, NFAT-luciferase reporter, Co-IP (SUMO2-CnA), sumoylation-deficient mutant (ΔGG), AAV9 in vivo cardiac expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct CnA interaction shown by Co-IP, ΔGG mutant establishes conjugation-independence, in vivo validation\",\n      \"pmids\": [\"27767176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ATF5 is modified by SUMO2/3 at a conserved consensus site; SUMOylation is elevated in G1 and reduced in G2/M, disrupts ATF5 interaction with centrosomal proteins, and dislodges ATF5 from the centrosome at end of M phase. Blocking ATF5 SUMOylation deregulates the centrosome cycle and causes genomic instability and G2/M arrest.\",\n      \"method\": \"SUMO site mutagenesis, cell cycle synchronization, Co-IP with centrosomal proteins, centrosome cycle assays, genomic instability scoring\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis plus cell cycle-resolved phenotype, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"29326161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SENP3 deconjugates SUMO2/3 from MKK7 in macrophages, promoting MKK7 binding to JNK and subsequent JNK phosphorylation upon LPS stimulation; ROS-dependent SENP3 accumulation after LPS drives this deSUMOylation, potentiating TLR4-mediated inflammatory signaling.\",\n      \"method\": \"Senp3 conditional knockout in myeloid cells, LPS challenge, JNK phosphorylation assays, MKK7 Co-IP, in vivo sepsis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout mouse with in vivo phenotype, substrate identification, and defined biochemical mechanism\",\n      \"pmids\": [\"29352108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SENP3 expression is downregulated during osteoclast differentiation; loss of SENP3 in BMDMs increases SUMO3 modification of IRF8 at K310, upregulating NFATc1 expression and promoting osteoclastogenesis; SENP3-conditional knockout mice show enhanced bone loss after ovariectomy.\",\n      \"method\": \"SENP3 conditional knockout in BMDMs, osteoclast differentiation assays, IRF8 SUMOylation site mutagenesis (K310), Co-IP, in vivo OVX model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout in vivo with substrate site mutagenesis and NFATc1 pathway readout\",\n      \"pmids\": [\"32049023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Conditional deletion of Sumo2 predominantly in forebrain neurons causes marked impairments in episodic and fear memory and a significant deficit in hippocampal long-term potentiation maintenance, demonstrating that SUMO2 conjugation is critically required for synaptic plasticity and cognitive function.\",\n      \"method\": \"Conditional Sumo2 knockout mice, behavioral testing (episodic, fear memory), LTP electrophysiology, gene expression analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined electrophysiological and behavioral phenotypes, multiple cognitive tests\",\n      \"pmids\": [\"32910521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SUMO2 is modified by PIAS4 (E3 ligase) during oxidative stress on TDP-43 at stress granules; SUMO2/3-ylation of TDP-43 by PIAS4 protects it against irreversible aggregation. RNA binding to TDP-43 antagonizes PIAS4-mediated SUMO2/3-ylation, while RNA dissociation promotes it.\",\n      \"method\": \"PIAS4 depletion, pharmacological inhibition of TDP-43 SUMOylation, stress granule assembly/disassembly assays, RNA binding mutants, Co-IP\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (genetic, pharmacological, RNA binding mutants) defining E3 ligase, stimulus, and functional consequence\",\n      \"pmids\": [\"39982984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of SENP7 catalytic domain in complex with SUMO2 identifies Loop1 of SENP7 as the structural element responsible for SUMO2/3 isoform specificity, making specific contacts with SUMO2 not seen with other SENP family members.\",\n      \"method\": \"X-ray crystallography of SENP7-SUMO2 complex, structural comparison, Loop1 mutagenesis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation of key structural determinants\",\n      \"pmids\": [\"36334780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SMT3IP1 (nucleolar SUMO-specific protease) preferentially removes SUMO-2 from nucleophosmin (NPM); NPM was identified as an SMT3IP1 binding partner by yeast two-hybrid, and a catalytically inactive SMT3IP1 mutant increased SUMO-2-modified NPM accumulation in a dominant-negative manner.\",\n      \"method\": \"Yeast two-hybrid, dominant-negative catalytic mutant, Co-IP, immunofluorescence\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — substrate identified by Y2H and dominant-negative approach, single lab\",\n      \"pmids\": [\"18639523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARHGAP21 (a RhoGAP protein) is specifically modified by SUMO2/3 at K1443, confirmed by in vitro SUMOylation assay and Co-IP; ARHGAP21 co-localizes with SUMO2/3 in cytoplasm and membrane compartments.\",\n      \"method\": \"Co-immunoprecipitation, in vitro SUMOylation assay, immunofluorescence, mass spectrometry identification of modified form\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro reconstitution plus in vivo Co-IP and site mapping, single lab\",\n      \"pmids\": [\"22922005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SUMO-2 promotes formation of the active eIF4F complex by enhancing interaction between eIF4E and eIF4G, stimulating cap-dependent translation of a subset of proteins including cyclin D1 and c-Myc; SUMO-2 overexpression partially rescues the inhibitory effect of the eIF4E/eIF4G interaction disruptor 4EGI-1.\",\n      \"method\": \"Co-IP of eIF4E-eIF4G, SUMO-2 overexpression and knockdown, 4EGI-1 rescue, translation reporter assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with functional translation readout, single lab, mechanism not fully resolved\",\n      \"pmids\": [\"24971752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of SENP1 in noncovalent complex with SUMO2 at 2.62 Å reveals that complex formation is driven by polar interactions; the SUMO2 C-terminal QQTGG motif protrudes into the SENP1 catalytic triad, providing the structural basis for SUMO maturation and deSUMOylation.\",\n      \"method\": \"X-ray crystallography (2.62 Å, R/Rfree 22.92%/27.66%)\",\n      \"journal\": \"Acta crystallographica. Section F, Structural biology communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure defining catalytic mechanism and protein-protein interface\",\n      \"pmids\": [\"31045562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mouse SUMO-2 inhibits IL-12 secretion in mature dendritic cells by blocking translocation of the p65 subunit of NFκB into the nucleus; SUMO-2 directly modifies IκBα.\",\n      \"method\": \"Ectopic SUMO-2 expression in DCs, NFκB nuclear translocation assay, IL-12 ELISA, Co-IP of SUMO-2 with IκBα\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP plus functional cytokine and NF-κB readout, single lab\",\n      \"pmids\": [\"21632113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Depletion of SUMO2 by shRNA enhances and accelerates somatic cell reprogramming to iPSCs (both mouse and human), identifying SUMO2 as a barrier to pluripotency acquisition; the SUMO2 pathway acts independently of c-MYC and in parallel with small-molecule reprogramming enhancers.\",\n      \"method\": \"Serial shRNA screen, iPSC formation assays, chimera formation, human iPSC generation\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen plus multiple validation approaches (mouse and human), but mechanistic pathway not fully defined\",\n      \"pmids\": [\"26947976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In mouse brain, Sumo2 is specifically detected at extranuclear compartments including synapses (distinct from nuclear-predominant Sumo1); immunoprecipitation coupled with MS identified shared and specific neuronal targets of Sumo1 versus Sumo2 in vivo.\",\n      \"method\": \"His6-HA-Sumo2 knockin mice, whole-brain imaging, subcellular fractionation, Co-IP/MS, proximity ligation assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockin mouse model with HA-epitope specificity, whole-brain imaging and proteomics, multiple orthogonal validation methods\",\n      \"pmids\": [\"37009224\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SUMO2 is a ubiquitin-like modifier that, together with SAE1/SAE2 (E1) and Ubc9 (E2), forms polymeric chains on substrates via its internal ψKXE motif; substrate and chain specificity are conferred by SUMO2/3-selective E3 ligases (PIASy, RanBP2, ZNF451-1, PIAS4, MUL1) and reversed by SUMO2/3-selective proteases (SENP3, SENP6, SENP7, SUSP1/SENP8); poly-SUMO2 chains are recognized by STUbL RNF4 to couple sumoylation to ubiquitin-proteasome degradation, while non-degradative SUMO2 polymer signaling regulates centromere assembly, DNA damage response, transcription, replication origin firing, and synaptic plasticity, and SUMO2 can additionally act in a conjugation-independent manner to modulate protein interactions (e.g., CnA nuclear localization).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SUMO2 is a ubiquitin-like post-translational modifier that forms polymeric chains on protein substrates through its internal ψKXE motif, catalyzed by SAE1/SAE2 (E1), Ubc9 (E2), and paralog-selective E3 ligases including PIASy, RanBP2, ZNF451-1, PIAS4, and PIAS1, with chain disassembly mediated by SUMO2/3-specific proteases SENP3, SENP6, and SENP7 whose isoform selectivity is structurally encoded by their Loop1 insertions [PMID:11451954, PMID:15933717, PMID:24424631, PMID:36334780]. Poly-SUMO2 chains serve as signals recognized by the SUMO-targeted ubiquitin ligase RNF4 to couple sumoylation to ubiquitin-dependent proteasomal degradation of substrates such as BMAL1, KDM5B, and misfolded CFTR, while proteolysis-independent SUMO2 polymer signaling regulates centromere assembly (via CCAN subunits), replication origin firing (via cyclin E), transcription–replication conflict resolution (via PCNA-recruited histone chaperones CAF1 and FACT), and innate immune homeostasis by suppressing a noncanonical type I interferon response [PMID:25772364, PMID:26627832, PMID:31485003, PMID:23673635, PMID:30006506, PMID:29891701]. SUMO2 chain architecture is further regulated by acetylation at K11, which redirects linkage specificity, and by crosstalk with phosphorylation on substrates [PMID:30201799, PMID:20797634]. Sumo2 is essential for mouse embryonic development and, in the adult brain, is required at synapses for hippocampal long-term potentiation and memory formation [PMID:24891386, PMID:32910521].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that SUMO-2, unlike SUMO-1, contains an internal ψKXE motif enabling polymeric chain formation via SAE1/SAE2 and Ubc9, revealing a fundamentally different signaling capacity for this paralog.\",\n      \"evidence\": \"In vitro reconstitution with purified E1/E2 plus in vivo detection of endogenous SUMO-2 chains\",\n      \"pmids\": [\"11451954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chain linkage specificity (which lysines are used) not determined\", \"Biological function of poly-SUMO2 chains unknown\", \"No E3 ligase involvement assessed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"High-resolution crystal structure of SUMO-2 revealed the ubiquitin-like βbαββαβ fold and a distinct C-terminal surface charge distribution that distinguishes it from SUMO-1, providing a structural basis for paralog-specific interactions.\",\n      \"evidence\": \"X-ray crystallography at 1.2 Å resolution\",\n      \"pmids\": [\"15479240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of SUMO-2 in complex with binding partners\", \"Functional significance of surface charge differences not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Proteomic identification of endogenous SUMO-2 conjugates and demonstration of their predominantly nuclear localization established the first substrate landscape for SUMO-2 in human cells.\",\n      \"evidence\": \"His6-SUMO-2 affinity purification from HeLa nuclear fractions with MS identification and immunoblot validation\",\n      \"pmids\": [\"15175327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Modification sites on substrates not mapped\", \"Functional consequences for individual substrates unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that PIASy functions as a SUMO-2-specific E3 ligase on mitotic chromosomes, required for Topoisomerase-II SUMOylation and sister chromatid segregation, established the first biological role for targeted SUMO-2 conjugation in cell division.\",\n      \"evidence\": \"Xenopus egg extract depletion/reconstitution with PIASy mutants and chromosome segregation assays\",\n      \"pmids\": [\"15933717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PIASy achieves SUMO-2 specificity not structurally resolved\", \"Whether other mitotic E3 ligases contribute unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"NMR-based mapping of the SUMO-interacting motif (SIM) binding surface on SUMO-2 showed that SIMs dock as β-strands along β2, with paralog specificity conferred by flanking acidic or phosphorylated residues, providing the molecular basis for SUMO-2-selective protein recognition.\",\n      \"evidence\": \"NMR spectroscopy, yeast two-hybrid, and bioinformatic analysis\",\n      \"pmids\": [\"16524884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SIM-SUMO2 interactions not yet validated for most endogenous targets\", \"Contribution of phosphorylation-dependent SIM switching in vivo unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Quantitative SILAC proteomics demonstrated that SUMO-1 and SUMO-2 modify substantially non-overlapping substrate sets, and identification of SUSP1/SENP8 as a SUMO-2/3-preferring protease established that both conjugation and deconjugation are paralog-selective.\",\n      \"evidence\": \"SILAC-labeled HeLa cells with His6-SUMO isoforms; vinyl sulfone inhibitor profiling and RNAi for SUSP1\",\n      \"pmids\": [\"17000644\", \"17000875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of substrate selectivity between SUMO-1 and SUMO-2 not resolved\", \"Full catalog of SUMO-2-specific proteases incomplete\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Studies on BMAL1 and Borealin revealed that poly-SUMO2/3 modification serves as a signal for ubiquitin-dependent proteasomal degradation and that the conjugation–deconjugation cycle (RanBP2/SENP3) is dynamically regulated during the cell cycle, linking SUMO-2 to both circadian and mitotic regulatory circuits.\",\n      \"evidence\": \"Mutagenesis of BMAL1 K259, SUMO protease manipulation, proteasome inhibition; in vitro RanBP2-mediated Borealin SUMOylation with SENP3 Co-IP and cell synchronization\",\n      \"pmids\": [\"18644859\", \"18946085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the ubiquitin ligase coupling SUMO2-BMAL1 to ubiquitination not determined at this point\", \"Stoichiometry and kinetics of mitotic SUMO2/3 cycling not measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Proteome-scale mapping of SUMO-2 acceptor lysines revealed canonical ψKXE, inverted, and hydrophobic-cluster motifs, and identified crosstalk with phosphorylation via a conserved spacer, establishing the modification site grammar at systems level.\",\n      \"evidence\": \"Site-specific mass spectrometry identifying 103 SUMO-2 sites across endogenous proteins\",\n      \"pmids\": [\"20797634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of non-canonical motif usage not tested\", \"Kinase-SUMOylation crosstalk validated for only a few substrates\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"SUMO-2 modification of cyclin E on chromatin during early S phase was shown to limit replication origin firing independently of Cdk2, and PIAS1 was identified as an E3 for SUMO-2 conjugation of huntingtin promoting its insoluble accumulation, expanding the functional scope to DNA replication control and neurodegeneration-linked proteostasis.\",\n      \"evidence\": \"Xenopus cell-free system with cyclin E depletion/reconstitution; systematic E3 screen with HTT mutagenesis and Drosophila model\",\n      \"pmids\": [\"23673635\", \"23871671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SUMO2-cyclin E limits origin firing not defined\", \"Whether SUMO2-HTT aggregation is protective or pathogenic in mammalian neurons unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Three advances converged: (1) proteome-wide site-level cataloging of >1000 SUMO-2 sites; (2) demonstration that SUMO2 is essential for mouse embryogenesis while SUMO3 is dispensable, attributable to expression level; (3) identification of the ATM/ATR→DBC1→SUMO2/3→SIRT1→p53 apoptotic axis under genotoxic stress.\",\n      \"evidence\": \"His6-SUMO2(T90K)/diGly proteomics; Sumo2/Sumo3 knockout mice; Co-IP with phospho-switch mutagenesis and apoptosis assays\",\n      \"pmids\": [\"24782567\", \"24891386\", \"25406032\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why SUMO2 expression level exceeds SUMO3 in embryonic tissues not explained\", \"Full substrate landscape under DNA damage only partially characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural determination of the SENP6 Loop1 insertion in complex with SUMO2 provided the molecular basis for SUMO2/3-selective chain editing, explaining how poly-SUMO2 chain length is controlled by a dedicated protease architecture.\",\n      \"evidence\": \"Crystal structure at 2.15 Å of chimeric SENP2-Loop1 with SUMO2 plus in vitro activity assays\",\n      \"pmids\": [\"24424631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length SENP6 structure with poly-SUMO2 substrate not available\", \"In vivo validation of Loop1 specificity determinants not yet performed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Quantitative SUMO-2 proteomics during DNA damage revealed that RNF4 (STUbL) ubiquitylates SUMOylated chromatin modifiers including KDM5B for proteasomal degradation while recruiting the paralog KDM5C, establishing the SUMO2→RNF4→ubiquitin cascade as a remodeling mechanism for the chromatin damage response.\",\n      \"evidence\": \"SILAC-based SUMO-2 proteomics after MMS, RNF4 knockdown, ChIP for histone marks\",\n      \"pmids\": [\"25772364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of RNF4 for specific SUMO2 chain types not resolved\", \"How replacement chromatin modifier recruitment is coordinated unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"ZNF451-1 was identified as a SUMO2/3-specific E3 ligase for PML, and SUMO2 was shown to activate calcineurin-NFAT signaling independently of its conjugation activity via direct binding to CnA, revealing a conjugation-independent mode of SUMO2 action.\",\n      \"evidence\": \"In vitro SUMOylation and RNAi for ZNF451-1; Co-IP of SUMO2-CnA with ΔGG mutant and AAV9 cardiac delivery\",\n      \"pmids\": [\"27343429\", \"27767176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of conjugation-independent CnA interaction unknown\", \"Physiological contexts of conjugation-independent SUMO2 functions poorly cataloged\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Multiple discoveries expanded SUMO2 function to transcription–replication conflict resolution (SUMO2-PCNA recruits CAF1/FACT at fragile sites), chain architecture regulation (K11 acetylation redirects chain linkages), innate immune homeostasis (SUMO2/3 suppress noncanonical type I IFN), and TLR4 inflammatory signaling (SENP3-mediated MKK7 deSUMOylation activates JNK).\",\n      \"evidence\": \"SUMO2-PCNA interactome with SIM mutants and ChIP; in vitro chain assays with acetyl-mimetic SUMO2; Sumo2/Sumo3 double KO IFN reporter; Senp3 conditional KO macrophages with LPS\",\n      \"pmids\": [\"30006506\", \"30201799\", \"29891701\", \"29352108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase responsible for K11 acetylation not identified\", \"Mechanism of noncanonical IFN induction upon loss of SUMO2/3 undefined\", \"Whether PCNA SUMO2 modification is Ubc9-only or E3-dependent unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"SENP6 was shown to control centromere integrity by editing poly-SUMO2/3 chains on CCAN subunits in a degradation-independent manner, establishing proteolysis-independent SUMO2 polymer signaling as a distinct functional paradigm from the STUbL-dependent pathway.\",\n      \"evidence\": \"SENP6 knockdown with quantitative SUMO proteomics, centromere assembly assays, cell cycle analysis, and micronuclei scoring\",\n      \"pmids\": [\"31485003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How poly-SUMO2 on CCAN disrupts centromere architecture mechanistically not determined\", \"Whether SENP6 acts co-translationally or post-assembly unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Conditional forebrain deletion of Sumo2 demonstrated that SUMO2 conjugation is essential for hippocampal LTP maintenance and episodic/fear memory, establishing a non-redundant role in adult neuronal physiology.\",\n      \"evidence\": \"Forebrain-specific Sumo2 conditional knockout mice with electrophysiology and behavioral testing\",\n      \"pmids\": [\"32910521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Key synaptic SUMO2 substrates mediating plasticity not identified\", \"Whether SUMO3 compensates partially in these neurons unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Crystal structure of SENP7 with SUMO2 confirmed that Loop1 is the conserved structural determinant of SUMO2/3 selectivity across the SENP6/7 subfamily, and SUMO2 was shown to localize prominently to synapses (not only nuclei) in mouse brain.\",\n      \"evidence\": \"X-ray crystallography of SENP7-SUMO2 complex; His6-HA-Sumo2 knockin mice with subcellular fractionation and MS\",\n      \"pmids\": [\"36334780\", \"37009224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Synaptic SUMO2 targets and their functional roles remain largely uncharacterized\", \"No full-length SENP7 structure in complex with poly-SUMO2 chain\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: which acetyltransferase modifies SUMO2 at K11 in vivo; how poly-SUMO2 chains on CCAN mechanistically disrupt centromere assembly; the identity of synaptic SUMO2 substrates underlying LTP; the mechanism by which loss of SUMO2/3 triggers noncanonical type I interferon; and the full scope of conjugation-independent SUMO2 functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"K11 acetyltransferase identity\", \"Structural basis of poly-SUMO2 chain recognition at centromeres vs. STUbL pathway\", \"Synaptic SUMO2 substrate identification\", \"Mechanism of SUMO2/3-dependent IFN suppression\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0031386\", \"supporting_discovery_ids\": [0, 10, 13]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [4, 12, 19, 22]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [38]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 10, 13, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 8, 12, 22, 26]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [12, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [21, 27]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [29, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"UBC9\", \"SAE1\", \"SAE2\", \"RNF4\", \"SENP3\", \"SENP6\", \"SENP7\", \"PIASy\"],\n    \"other_free_text\": []\n  }\n}\n```"}